Claims for Patent: 9,283,209

Summary for Patent: 9,283,209

Title:	Oral formulations of deferasirox
Abstract:	Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
Inventor(s):	Ghosh; Indrajit (Hillsborough, NJ), Zhang; Jia-Ai (Skillman, NJ)
Assignee:	NOVARTIS AG (Basel, CH)
Application Number:	14/198,872
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,283,209
Patent Claims:	1. A tablet for oral administration consisting of 90 mg deferasirox; 53.61 mg microcrystalline cellulose; 3.65 mg poly vinyl pyrrolidone K-30; 11.34 mg crospovidone; 0.16 mg poloxamer; 0.81 mg fumed silica; 2.43 mg magnesium stearate; and 4.86 mg seal-coat. 2. A tablet for oral administration consisting of 180 mg deferasirox; 107.23 mg microcrystalline cellulose; 7.29 mg poly vinyl pyrrolidone K-30; 22.68 mg crospovidone; 0.32 mg poloxamer; 1.62 mg fumed silica; 4.86 mg magnesium stearate; and 9.72 mg seal-coat. 3. A tablet for oral administration consisting of 360 mg deferasirox; 215.45 mg microcrystalline cellulose; 14.58 mg poly vinyl pyrrolidone K-30; 45.36 mg crospovidone; 0.65 mg poloxamer; 3.24 mg fumed silica; 9.72 mg magnesium stearate; and 19.44 mg seal-coat.